Tom Baker Cancer Center

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Acute myeloid leukaemia3 trials
• Metastatic breast cancer2 trials
• Acute lymphoblastic leukaemia1 trial
• Amyloidosis1 trial
• Childhood cancers1 trial
• Follicular lymphoma1 trial
• Liver and biliary tract cancer1 trial
• Lung cancer1 trial
• Multiple myeloma1 trial
• Myelodysplastic syndromes1 trial
• Prostate cancer1 trial
• Sarcoma1 trial

Phase

• Phase 38 trials
• Phase 22 trials
• Phase 1/21 trial

Status

• Active, not recruiting4 trials
• Completed3 trials
• Recruiting2 trials
• Terminated2 trials

Lead sponsor

• Eli Lilly and Company2 trials
• Ariad Pharmaceuticals1 trial
• Centre hospitalier de l'Université de Montréal (CHUM)1 trial
• Daiichi Sankyo1 trial
• Gilead Sciences1 trial
• and 5 more

Running trials

• Recruiting

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· Phase 3· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Active, not recruiting

  An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

  NCT05876754· Phase 3· Servier Affaires Médicales· Source

• Active, not recruiting

  A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

  NCT05250973· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  NCT04988555· Phase 1/2· Sumitomo Pharma America, Inc.· Source

  Contact: Lynn Savoie, MD

• Active, not recruiting

  PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer

  NCT04557501· Phase 3· Centre hospitalier de l'Université de Montréal (CHUM)· Source

• Active, not recruiting

  A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

  NCT02107703· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• Childhood cancers1 recruiting
• Follicular lymphoma1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting

Closed trials

• Terminated

  Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

  NCT04778397· Phase 3· Gilead Sciences· Source

• Completed

  A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

  NCT03535740· Phase 2· Ariad Pharmaceuticals· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Terminated

  Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

  NCT03616470· Phase 3· GlycoMimetics Incorporated· Source

• Completed

  A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

  NCT02451943· Phase 3· Eli Lilly and Company· Source